IL2 and type 1 diabetes mellitus: ITAD is the first phase 2 trial using ultra-low dose aldesleukin in children and adolescents with a very recent diagnosis of T1D, who still have detectable C-peptide levels that indicate residual β-cell function, leading to the opportunity of assessing any changes in this C-peptide production because of the exposure to aldesleukin.